HUP0400155A2 - N-fenil-arilszulfonamidok, intermediereik, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra - Google Patents
N-fenil-arilszulfonamidok, intermediereik, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukraInfo
- Publication number
- HUP0400155A2 HUP0400155A2 HU0400155A HUP0400155A HUP0400155A2 HU P0400155 A2 HUP0400155 A2 HU P0400155A2 HU 0400155 A HU0400155 A HU 0400155A HU P0400155 A HUP0400155 A HU P0400155A HU P0400155 A2 HUP0400155 A2 HU P0400155A2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- methyl
- group
- processes
- producing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- -1 5-methyl-2-furyl group Chemical group 0.000 abstract 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
- 208000006593 Urologic Neoplasms Diseases 0.000 abstract 1
- 208000012931 Urologic disease Diseases 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 229940125716 antipyretic agent Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 229940124641 pain reliever Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Furan Compounds (AREA)
Abstract
A találmány tárgyát az általános képletű vegyületek - ahol R1 -COOH stb. csoport; R2 hidrogénatom, metilcsoport, stb.; R3 és R4 metil- és metilcsoport kombinációja, stb.; R5 izopropilcsoport, stb.; Ar tiazolil-, piridil-, 5-metil-2- furil-csoport, mindegyik adott esetben metilcsoporttal szubsztituált; n értéke 0 vagy 1 - szintézisintermediereik, az előállításukra szolgáló eljárás és alkalmazásuk képezik. Az (I) általános képletű vegyületek egy prosztaglandin E2 receptorhoz, különösen egy EP1 altípusú receptorhoz kapcsolódnak és azt antagonizálják. A vegyületet a protein- kötés kevéssé befolyásolja, így kielégítő az in vivo aktivitása. Ezért fájdalomcsillapítók, láz elleni szerek, gyakori vizelés és/vagy az alsó húgyúti rendszerbetegségek tünetegyüttesének, vagy ráknak a megelőzésére, vagy kezelésére szolgáló gyógyszerkészítmények hatóanyagaiként alkalmazhatók. Ó
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001068498 | 2001-03-12 | ||
| JP2001-68498 | 2001-03-12 | ||
| JP2001-281569 | 2001-09-17 | ||
| JP2001281569 | 2001-09-17 | ||
| JP2002007760 | 2002-01-16 | ||
| JP2002-7760 | 2002-01-16 | ||
| PCT/JP2002/002245 WO2002072564A1 (fr) | 2001-03-12 | 2002-03-11 | Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0400155A2 true HUP0400155A2 (hu) | 2004-08-30 |
| HUP0400155A3 HUP0400155A3 (en) | 2007-05-02 |
| HU230056B1 HU230056B1 (hu) | 2015-06-29 |
Family
ID=27346214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400155A HU230056B1 (hu) | 2001-03-12 | 2002-03-11 | N-fenil-arilszulfonamidok, intermediereik, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7235667B2 (hu) |
| EP (2) | EP1612208B1 (hu) |
| JP (3) | JP3555620B2 (hu) |
| KR (1) | KR100886854B1 (hu) |
| CN (1) | CN1294126C (hu) |
| AT (2) | ATE522513T1 (hu) |
| AU (1) | AU2002238855B2 (hu) |
| BR (1) | BR0208027A (hu) |
| CA (1) | CA2439604C (hu) |
| CZ (1) | CZ304035B6 (hu) |
| DE (1) | DE60220255T2 (hu) |
| DK (2) | DK1369419T3 (hu) |
| ES (1) | ES2286230T3 (hu) |
| HU (1) | HU230056B1 (hu) |
| IL (2) | IL157701A0 (hu) |
| MX (1) | MXPA03008134A (hu) |
| NO (1) | NO329682B1 (hu) |
| NZ (1) | NZ528120A (hu) |
| PL (1) | PL218750B1 (hu) |
| PT (2) | PT1369419E (hu) |
| RU (1) | RU2299202C2 (hu) |
| TW (1) | TWI317359B (hu) |
| WO (1) | WO2002072564A1 (hu) |
| ZA (1) | ZA200306884B (hu) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003264388A1 (en) * | 2002-09-09 | 2004-03-29 | Ono Pharmaceutical Co., Ltd. | Process for producing 4-methyl-1,3-thiazol-2-ylsulfonyl halide |
| AU2004207675B2 (en) * | 2003-01-29 | 2010-05-20 | Asterand Uk Acquisition Limited | EP4 receptor antagonists |
| GB0317500D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Treatment of bph |
| WO2005000356A1 (ja) * | 2003-06-27 | 2005-01-06 | Ono Pharmaceutical Co., Ltd. | 尿路疾患治療剤 |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2006004115A1 (ja) * | 2004-07-05 | 2006-01-12 | Chugai Seiyaku Kabushiki Kaisha | 過活動膀胱治療剤 |
| JP2008189549A (ja) * | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| JP2009057282A (ja) * | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| TW200817319A (en) | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
| CA2677769C (en) * | 2007-02-16 | 2016-01-19 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for urinary excretion disorder |
| JP5311057B2 (ja) * | 2007-08-01 | 2013-10-09 | 大正製薬株式会社 | Ｓ１ｐ１結合阻害物質 |
| EP2116618A1 (en) * | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| CN102076660B (zh) | 2008-06-23 | 2014-01-08 | 安斯泰来制药有限公司 | 磺胺化合物或其盐 |
| TW201107309A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
| CN103209960A (zh) * | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | 用作cyp17抑制剂的磺酰胺化合物 |
| JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
| US20140039004A1 (en) | 2012-07-31 | 2014-02-06 | Ono Pharmaceutical Co., Ltd. | Method of treating of gastroesophageal reflux disease |
| JP6103893B2 (ja) * | 2012-11-15 | 2017-03-29 | サントリー食品インターナショナル株式会社 | コーヒーオイルの製造方法 |
| DK3138633T3 (en) * | 2014-04-30 | 2019-03-18 | Ind Penalver Sl | Programmable concentric head for applying liquid to lids with different designs |
| RS60927B1 (sr) * | 2015-11-13 | 2020-11-30 | Daewoong Pharmaceutical Co Ltd | Blokator natrijumovih kanala |
| RU2659955C1 (ru) * | 2017-10-26 | 2018-07-04 | Галина Ильхамовна Лукина | Способ диагностики высоких гастроэзофагеальных рефлюксов |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2419923A1 (de) * | 1973-04-28 | 1974-11-28 | Fujisawa Pharmaceutical Co | Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel |
| JPS5748534B2 (hu) | 1974-03-04 | 1982-10-16 | ||
| DE2555048A1 (de) * | 1975-12-06 | 1977-06-30 | Pfersee Chem Fab | Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen |
| JPS5293469A (en) * | 1976-02-02 | 1977-08-05 | Fuji Photo Film Co Ltd | Method of curing gelatin |
| JPH05293469A (ja) | 1992-04-17 | 1993-11-09 | Toda Constr Co Ltd | 滅菌精製水の製造方法およびその装置 |
| TW523506B (en) * | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| WO2000069465A1 (fr) * | 1999-05-12 | 2000-11-23 | Ono Pharmaceutical Co., Ltd. | Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif |
| AU6180600A (en) | 1999-07-29 | 2001-02-19 | Ono Pharmaceutical Co. Ltd. | Sulfonamide derivatives and remedies for allodynia |
| JP4175113B2 (ja) * | 2001-03-14 | 2008-11-05 | 小野薬品工業株式会社 | Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤 |
-
2002
- 2002-03-11 AU AU2002238855A patent/AU2002238855B2/en not_active Ceased
- 2002-03-11 DK DK02705096T patent/DK1369419T3/da active
- 2002-03-11 BR BR0208027-3A patent/BR0208027A/pt not_active IP Right Cessation
- 2002-03-11 DE DE60220255T patent/DE60220255T2/de not_active Expired - Lifetime
- 2002-03-11 US US10/471,673 patent/US7235667B2/en not_active Expired - Fee Related
- 2002-03-11 NZ NZ528120A patent/NZ528120A/en not_active IP Right Cessation
- 2002-03-11 PL PL365100A patent/PL218750B1/pl unknown
- 2002-03-11 AT AT05109059T patent/ATE522513T1/de active
- 2002-03-11 KR KR1020037011921A patent/KR100886854B1/ko not_active IP Right Cessation
- 2002-03-11 WO PCT/JP2002/002245 patent/WO2002072564A1/ja active IP Right Grant
- 2002-03-11 EP EP05109059A patent/EP1612208B1/en not_active Expired - Lifetime
- 2002-03-11 TW TW091104451A patent/TWI317359B/zh not_active IP Right Cessation
- 2002-03-11 PT PT02705096T patent/PT1369419E/pt unknown
- 2002-03-11 HU HU0400155A patent/HU230056B1/hu not_active IP Right Cessation
- 2002-03-11 AT AT02705096T patent/ATE362924T1/de active
- 2002-03-11 DK DK05109059.5T patent/DK1612208T3/da active
- 2002-03-11 PT PT05109059T patent/PT1612208E/pt unknown
- 2002-03-11 MX MXPA03008134A patent/MXPA03008134A/es active IP Right Grant
- 2002-03-11 CA CA2439604A patent/CA2439604C/en not_active Expired - Fee Related
- 2002-03-11 RU RU2003127677/04A patent/RU2299202C2/ru not_active IP Right Cessation
- 2002-03-11 EP EP02705096A patent/EP1369419B1/en not_active Expired - Lifetime
- 2002-03-11 ES ES02705096T patent/ES2286230T3/es not_active Expired - Lifetime
- 2002-03-11 IL IL15770102A patent/IL157701A0/xx unknown
- 2002-03-11 CN CNB028097904A patent/CN1294126C/zh not_active Expired - Fee Related
- 2002-03-11 JP JP2002571480A patent/JP3555620B2/ja not_active Expired - Fee Related
- 2002-03-11 CZ CZ20032452A patent/CZ304035B6/cs not_active IP Right Cessation
-
2003
- 2003-09-02 IL IL157701A patent/IL157701A/en not_active IP Right Cessation
- 2003-09-03 ZA ZA2003/06884A patent/ZA200306884B/en unknown
- 2003-09-10 NO NO20034007A patent/NO329682B1/no not_active IP Right Cessation
- 2003-12-24 JP JP2003427226A patent/JP3741120B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-26 JP JP2005245763A patent/JP4432051B2/ja not_active Expired - Fee Related
- 2005-09-30 US US11/239,406 patent/US7629369B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/603,194 patent/US8088802B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0400155A2 (hu) | N-fenil-arilszulfonamidok, intermediereik, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| HUP0300826A2 (hu) | Egy epotilon-analóg polimorfjai, eljárás az elżállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| AU2002359164A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| NO168372C (no) | Fremgangsmaate for fremstilling av terapeutisk aktive tricykloforbindelser | |
| HUP0303022A2 (hu) | Kinazolin-ditozilátsó vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| WO2003024965A3 (en) | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv | |
| DE69839278D1 (de) | Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung | |
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| ATE479433T1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| GB2454615A (en) | Antidiabetic azabicyclo (3.1.0) hexan compounds | |
| WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
| HUP0302336A2 (hu) | 5-Klór-3-(4-metánszulfonilfenil)-6'-metil-[2,3']bipiridinil tiszta formában és eljárás előállítására | |
| SE0104331D0 (sv) | Novel compounds | |
| AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| NO330964B1 (no) | Kolkisosidanaloger | |
| WO2007127421A3 (en) | Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes | |
| JPH01199979A (ja) | 新規キノリンカルボン酸誘導体および該化合物を有効成分とする抗菌剤 | |
| AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
| WO2004029019A8 (en) | Compounds for the treatment of alzheimer’s disease | |
| TW200511990A (en) | Novel medical uses of 4, 5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| WO2003004460A3 (en) | Succinic acid derivatives | |
| HUP0300032A2 (en) | Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |